FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease

Kunlin Jin, Michelle LaFevre-Bernt, Yunjuan Sun, Sylvia Chen, Juliette Gafni, Danielle Crippen, Anna Logvinova, Christopher A Ross, David A. Greenberg, Lisa M. Ellerby

Research output: Contribution to journalArticle

Abstract

There is no satisfactory treatment for Huntington's disease (HD), a hereditary neurodegenerative disorder that produces chorea, dementia, and death. One potential treatment strategy involves the replacement of dead neurons by stimulating the proliferation of endogenous neuronal precursors (neurogenesis) and their migration into damaged regions of the brain. Because growth factors are neuroprotective in some settings and can also stimulate neurogenesis, we treated HD transgenic R6/2 mice from 8 weeks of age until death by s.c. administration of FGF-2, FGF-2 increased the number of proliferating cells in the subventricular zone by ≈30% in wild-type mice, and by ≈150% in HD transgenic R6/2 mice. FGF-2 also induced the recruitment of new neurons from the subventricular zone into the neostriatum and cerebral cortex of HD transgenic R6/2 mice. In the striatum, these neurons were DARPP-32-expressing medium spiny neurons, consistent with the phenotype of neurons lost in HD. FGF-2 was neuroprotective as well, because it blocked cell death induced by mutant expanded Htt in primary striatal cultures. FGF-2 also reduced polyglutamine aggregates, improved motor performance, and extended lifespan by ≈20%. We conclude that FGF-2 improves neurological deficits and longevity in a transgenic mouse model of HD, and that its neuroprotective and neuroproliferative effects may contribute to this improvement.

Original languageEnglish (US)
Pages (from-to)18189-18194
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume102
Issue number50
DOIs
StatePublished - Dec 13 2005

Fingerprint

Huntington Disease
Neurogenesis
Fibroblast Growth Factor 2
Transgenic Mice
Neurons
Lateral Ventricles
Neostriatum
Corpus Striatum
Chorea
Neuroprotective Agents
Neurodegenerative Diseases
Cerebral Cortex
Dementia
Neuroprotection
Intercellular Signaling Peptides and Proteins
Cell Death
Cell Count
Phenotype
Brain

Keywords

  • Polyglutamine
  • Trophic factor

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. / Jin, Kunlin; LaFevre-Bernt, Michelle; Sun, Yunjuan; Chen, Sylvia; Gafni, Juliette; Crippen, Danielle; Logvinova, Anna; Ross, Christopher A; Greenberg, David A.; Ellerby, Lisa M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 50, 13.12.2005, p. 18189-18194.

Research output: Contribution to journalArticle

Jin, Kunlin ; LaFevre-Bernt, Michelle ; Sun, Yunjuan ; Chen, Sylvia ; Gafni, Juliette ; Crippen, Danielle ; Logvinova, Anna ; Ross, Christopher A ; Greenberg, David A. ; Ellerby, Lisa M. / FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. In: Proceedings of the National Academy of Sciences of the United States of America. 2005 ; Vol. 102, No. 50. pp. 18189-18194.
@article{d4e8b6dd9ba4415ba31b63d807eb7251,
title = "FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease",
abstract = "There is no satisfactory treatment for Huntington's disease (HD), a hereditary neurodegenerative disorder that produces chorea, dementia, and death. One potential treatment strategy involves the replacement of dead neurons by stimulating the proliferation of endogenous neuronal precursors (neurogenesis) and their migration into damaged regions of the brain. Because growth factors are neuroprotective in some settings and can also stimulate neurogenesis, we treated HD transgenic R6/2 mice from 8 weeks of age until death by s.c. administration of FGF-2, FGF-2 increased the number of proliferating cells in the subventricular zone by ≈30{\%} in wild-type mice, and by ≈150{\%} in HD transgenic R6/2 mice. FGF-2 also induced the recruitment of new neurons from the subventricular zone into the neostriatum and cerebral cortex of HD transgenic R6/2 mice. In the striatum, these neurons were DARPP-32-expressing medium spiny neurons, consistent with the phenotype of neurons lost in HD. FGF-2 was neuroprotective as well, because it blocked cell death induced by mutant expanded Htt in primary striatal cultures. FGF-2 also reduced polyglutamine aggregates, improved motor performance, and extended lifespan by ≈20{\%}. We conclude that FGF-2 improves neurological deficits and longevity in a transgenic mouse model of HD, and that its neuroprotective and neuroproliferative effects may contribute to this improvement.",
keywords = "Polyglutamine, Trophic factor",
author = "Kunlin Jin and Michelle LaFevre-Bernt and Yunjuan Sun and Sylvia Chen and Juliette Gafni and Danielle Crippen and Anna Logvinova and Ross, {Christopher A} and Greenberg, {David A.} and Ellerby, {Lisa M.}",
year = "2005",
month = "12",
day = "13",
doi = "10.1073/pnas.0506375102",
language = "English (US)",
volume = "102",
pages = "18189--18194",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "50",

}

TY - JOUR

T1 - FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease

AU - Jin, Kunlin

AU - LaFevre-Bernt, Michelle

AU - Sun, Yunjuan

AU - Chen, Sylvia

AU - Gafni, Juliette

AU - Crippen, Danielle

AU - Logvinova, Anna

AU - Ross, Christopher A

AU - Greenberg, David A.

AU - Ellerby, Lisa M.

PY - 2005/12/13

Y1 - 2005/12/13

N2 - There is no satisfactory treatment for Huntington's disease (HD), a hereditary neurodegenerative disorder that produces chorea, dementia, and death. One potential treatment strategy involves the replacement of dead neurons by stimulating the proliferation of endogenous neuronal precursors (neurogenesis) and their migration into damaged regions of the brain. Because growth factors are neuroprotective in some settings and can also stimulate neurogenesis, we treated HD transgenic R6/2 mice from 8 weeks of age until death by s.c. administration of FGF-2, FGF-2 increased the number of proliferating cells in the subventricular zone by ≈30% in wild-type mice, and by ≈150% in HD transgenic R6/2 mice. FGF-2 also induced the recruitment of new neurons from the subventricular zone into the neostriatum and cerebral cortex of HD transgenic R6/2 mice. In the striatum, these neurons were DARPP-32-expressing medium spiny neurons, consistent with the phenotype of neurons lost in HD. FGF-2 was neuroprotective as well, because it blocked cell death induced by mutant expanded Htt in primary striatal cultures. FGF-2 also reduced polyglutamine aggregates, improved motor performance, and extended lifespan by ≈20%. We conclude that FGF-2 improves neurological deficits and longevity in a transgenic mouse model of HD, and that its neuroprotective and neuroproliferative effects may contribute to this improvement.

AB - There is no satisfactory treatment for Huntington's disease (HD), a hereditary neurodegenerative disorder that produces chorea, dementia, and death. One potential treatment strategy involves the replacement of dead neurons by stimulating the proliferation of endogenous neuronal precursors (neurogenesis) and their migration into damaged regions of the brain. Because growth factors are neuroprotective in some settings and can also stimulate neurogenesis, we treated HD transgenic R6/2 mice from 8 weeks of age until death by s.c. administration of FGF-2, FGF-2 increased the number of proliferating cells in the subventricular zone by ≈30% in wild-type mice, and by ≈150% in HD transgenic R6/2 mice. FGF-2 also induced the recruitment of new neurons from the subventricular zone into the neostriatum and cerebral cortex of HD transgenic R6/2 mice. In the striatum, these neurons were DARPP-32-expressing medium spiny neurons, consistent with the phenotype of neurons lost in HD. FGF-2 was neuroprotective as well, because it blocked cell death induced by mutant expanded Htt in primary striatal cultures. FGF-2 also reduced polyglutamine aggregates, improved motor performance, and extended lifespan by ≈20%. We conclude that FGF-2 improves neurological deficits and longevity in a transgenic mouse model of HD, and that its neuroprotective and neuroproliferative effects may contribute to this improvement.

KW - Polyglutamine

KW - Trophic factor

UR - http://www.scopus.com/inward/record.url?scp=29144517660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144517660&partnerID=8YFLogxK

U2 - 10.1073/pnas.0506375102

DO - 10.1073/pnas.0506375102

M3 - Article

VL - 102

SP - 18189

EP - 18194

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 50

ER -